At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02575 XUANZHUBIO-B
Trading 04-20 14:19:14
31.140
-2.420
-7.21%
High33.300Low31.000Vol1.46M
Open33.300D1 Closing33.560Amplitude6.85%
Mkt Cap16.13BTradable Cap5.00BTotal Shares518.00M
T/O46.13MT/O Rate0.91%Tradable Shares160.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR
Stock News  ·  04-19 18:20
XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR
Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%
Reuters  ·  04-19 18:07
Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%
Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares
Bulletin Express  ·  04-17 17:05
Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares
XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan
Stock News  ·  04-17 16:34
XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan
Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares
Reuters  ·  04-17 16:31
Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares
BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Reuters  ·  04-15
BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
Reuters  ·  04-15
BRIEF-Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment
Stock Track  ·  04-15
Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment
XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication
Stock News  ·  04-15
XuanZhu Bio-B Receives Approval for Phase III Trial of New Anaprazole Sodium Indication
XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication
Bulletin Express  ·  04-15
XUANZHUBIO-B Wins CDE Approval to Launch 556-Patient Phase III Trial of Anaprazole Sodium for H. pylori Eradication
Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial
Reuters  ·  04-15
Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial
Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication
THOMSON REUTERS  ·  04-15
Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication
Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal
Stock Track  ·  04-14
Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal
XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals
Stock News  ·  04-14
XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals
Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares
Bulletin Express  ·  04-12
Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares
XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan
Stock News  ·  04-12
XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan
BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Reuters  ·  04-10
BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology
Stock News  ·  04-10
Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology
BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology
Reuters  ·  04-09
BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology
XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology
Stock News  ·  04-09
XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology

Introduction

Company Name.
XUANZHUBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.
Issue price:
--